Abbott Laboratories Quarterly Income Statement
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Abbott Laboratories revenue and earnings
In the quarter ended Mar 31, 2026, Abbott Laboratories generated $11.16 billion in revenue, up 7.8% from the same quarter a year earlier. Net income was $1.08 billion (-18.7% year over year), for a net margin of 9.6% versus a median of 15.5% in the prior 5 quarters. Gross margin was 56.2% (down from 56.9%) and operating margin 12.0%.
Diluted earnings per share came in at $0.61, down from $0.76.
Summary generated from market data by MetaCap's automated system. Methodology
Abbott Laboratories income statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.16B | 11.46B | 11.37B | 11.14B | 10.36B | 10.97B | 10.63B | 10.38B | 9.96B | 10.24B | 10.14B | 9.98B |
| Revenue growth (YoY) | +7.78% | +4.42% | +6.90% | +7.37% | +3.95% | +7.16% | +4.85% | +4.00% | +2.23% | +1.49% | -2.56% | -11.36% |
| Cost of Revenue | 4.89B | 4.92B | 5.08B | 4.85B | 4.47B | 4.94B | 4.70B | 4.60B | 4.46B | 4.56B | 4.61B | 4.48B |
| Gross Profit | 6.27B | 6.54B | 6.29B | 6.29B | 5.89B | 6.03B | 5.94B | 5.77B | 5.50B | 5.68B | 5.54B | 5.50B |
| Operating Expenses | 4.93B | 4.29B | 4.24B | 4.24B | 4.20B | 4.12B | 4.08B | 4.11B | 4.12B | 3.90B | 3.89B | 3.95B |
| Research & Development | 767.00M | 735.00M | 766.00M | 725.00M | 716.00M | 749.00M | 713.00M | 698.00M | 684.00M | 700.00M | 672.00M | 715.00M |
| Selling, General & Admin | 3.74B | 3.13B | 3.05B | 3.09B | 3.06B | 2.91B | 2.90B | 2.94B | 2.96B | 2.72B | 2.72B | 2.74B |
| Operating Income | 1.34B | 2.25B | 2.06B | 2.05B | 1.69B | 1.91B | 1.86B | 1.67B | 1.39B | 1.78B | 1.65B | 1.54B |
| Interest Expense | 174.00M | 120.00M | 121.00M | 121.00M | 131.00M | 136.00M | 142.00M | 140.00M | 141.00M | 159.00M | 166.00M | 159.00M |
| Other Income (Expense) | 159.00M | 134.00M | 150.00M | 137.00M | 127.00M | 154.00M | 121.00M | -10.00M | 111.00M | 109.00M | 83.00M | 176.00M |
| Pretax Income | 1.45B | 2.36B | 2.18B | 2.15B | 1.78B | 2.03B | 1.94B | 1.61B | 1.44B | 1.79B | 1.67B | 1.64B |
| Income Tax | 372.00M | 582.00M | 536.00M | 371.00M | 453.00M | -7.20B | 294.00M | 305.00M | 211.00M | 201.00M | 235.00M | 261.00M |
| Net Income | 1.08B | 1.78B | 1.64B | 1.78B | 1.32B | 9.23B | 1.65B | 1.30B | 1.23B | 1.59B | 1.44B | 1.38B |
| Net Income growth (YoY) | -18.72% | -80.76% | -0.12% | +36.64% | +8.16% | +478.98% | +14.62% | -5.31% | -7.06% | +54.31% | +0.07% | -31.86% |
| EPS (Basic) | 0.62 | 1.01 | 0.94 | 1.02 | 0.76 | 5.29 | 0.94 | 0.74 | 0.70 | 0.92 | 0.82 | 0.79 |
| EPS (Diluted) | 0.61 | 1.01 | 0.94 | 1.01 | 0.76 | 5.26 | 0.94 | 0.74 | 0.70 | 0.91 | 0.82 | 0.78 |
| Shares Outstanding (Basic) | 1.74B | — | 1.74B | 1.74B | 1.74B | — | 1.74B | 1.74B | 1.74B | — | 1.74B | 1.74B |
| Shares Outstanding (Diluted) | 1.75B | — | 1.75B | 1.75B | 1.75B | — | 1.75B | 1.75B | 1.75B | — | 1.75B | 1.75B |
| EBITDA | 1.73B | 2.62B | 2.43B | 2.41B | 2.03B | 2.25B | 2.19B | 2.00B | 1.72B | 2.11B | 1.98B | 1.84B |
| Gross Margin | 56.20% | 57.05% | 55.36% | 56.44% | 56.86% | 54.97% | 55.83% | 55.64% | 55.21% | 55.51% | 54.60% | 55.07% |
| Operating Margin | 12.05% | 19.64% | 18.09% | 18.42% | 16.34% | 17.41% | 17.48% | 16.08% | 13.91% | 17.38% | 16.24% | 15.45% |
| Net Margin | 9.65% | 15.50% | 14.46% | 15.97% | 12.79% | 84.10% | 15.48% | 12.55% | 12.29% | 15.56% | 14.16% | 13.78% |
This table shows 12 quarterly periods of Abbott Laboratories's income statement, from Q1 2026 back to Q2 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ABT's reporting calendar. What is a income statement?